Roxadustat-d5

Roxadustat-d5 is deuterium labeled Roxadustat. Roxadustat is an oral hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI) that promotes erythropoiesis through increasing endogenous erythropoietin, improving iron regulation, and reducing hepcidin[1].

Product Specifications

CAS Number

[2043026-13-5]

UNSPSC

12352005

Hazard Statement

H302+H312+H332, H315, H319

Target

Ferroptosis; HIF/HIF Prolyl-Hydroxylase

Type

Isotope-Labeled Compounds

Related Pathways

Apoptosis; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Purity

98.80

Solubility

10 mM in DMSO

Smiles

O=C(O)CNC(C1=C(O)C2=C(C(C)=N1)C=C(OC3=C([2H])C([2H])=C([2H])C([2H])=C3[2H])C=C2)=O

Molecular Formula

C19H11D5N2O5

Molecular Weight

357.37

Precautions

H302+H312+H332, H315, H319

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Provenzano R, et al. Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving MaintenanceHemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study. Am J Kidney Dis. 2016 Jun;67 (6) :912-24.|[3]Wu K, et al. Stabilization of HIF-1α by FG-4592 promotes functional recovery and neural protection in experimental spinal cord injury. Brain Res. 2016 Feb 1;1632:19-26.